Manufacturer of Band-Aid Liquid Bandage and Dermabond topical adhesive is being acquired by Johnson & Johnson in a cash-for-stock exchange worth roughly $370 mil., the firms announce March 4. Closure will operate as a stand-alone entity reporting through J&J division Ethicon. Liquid Band-Aid sales grew roughly 20% over the prior-year period due to the domestic launch of the Skin Crack Gel line extension. However, sales were negatively impacted by private-label competition. J&J will incur a one-time, after-tax charge of $68 mil.; Closure shareholders will receive $27 for each outstanding share. The addition to the device unit closely follows J&J's purchase of Guidant in December...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.